Compound

Linezolid

Description

Linezolid is an FDA-approved drug for use against serious or problematic infections of resistant strains of gram-positive bacteria. It is currently under investigation as a repurposed drug for tuberculosis.

Related Links

Koh WJ, Kang YR, Jeon K, Kwon OJ, Lyu J, Kim WS, Shim TS.2012.Daily 300 mg dose of linezolid for multidrug-resistant and extensively drug-resistant tuberculosis: updated analysis of 51 patients.J Antimicrob Chemother. Jun;67(6):1503-7.

Regimen Associations

Bedaquiline - Pretomanid - Linezolid - Moxifloxacin

Bedaquiline - Pretomanid - Linezolid

Bedaquiline-Moxifloxacin-Linezolid-Pyrazinamide

Trial Associations

TBTC Study 30: A Phase I/II Pilot Study for Evaluation of Low Dose, Once Daily, Linezolid Plus Optimized Background Therapy (OBT) Versus Placebo Plus OBT for the Treatment of Multi-drug Resistant Tube

TBTC Study 30PK Linezolid Pharmacokinetics and Pharmacodynamics in the Treatment of Multi-Drug Resistant and Extensively-Drug Resistant Tuberculosis

Nix-TB (B-Pa-L)

endTB

TB-PRACTECAL

ZeNix (B-Pa-L) NC-007

BEAT-TB Building Evidence for Advancing New Treatment for Rifampicin Resistant Tuberculosis

endTB-Q

NC-009 Trial

DRAMATIC Trial

Linezolid

About Us

Navigate

Contact

Follow Us